North America Cardiac Markers Market Size and Forecast (2021-2031)

North America Cardiac Markers Market Size and Forecast (2021-2031)

North America Cardiac Markers Market Size and Forecast (2021 – 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Reagents and Kits, and Analyzers), Biomarker Type (Troponin, Creatine Kinase-MB, Myoglobin, B-Type Natriuretic Peptide, and Others), Indication (Congestive Heart Failure, Myocradial Infraction, Acute Coronary Syndrome, and Others), End User (Hospitals, Diagnostic Laboratories, Point-of-Care Testing Facilities, and Others), and Country (US, Canada, Mexico)

Send Enquiry
Item ID: TIPRE00039162 Category: Tag:

$2,485 – $3,885

Description

The global North America cardiac marker market is expected to reach US$ 2.87 billion by 2031 from US$ 1.17 billion in 2023. The market is estimated to grow with a CAGR of 11.8% from 2023 to 2031.

The North America cardiac marker market forecast presented in this report can help stakeholders in this marketplace plan their growth strategies. The rising prevalence of cardiovascular diseases and a surge in the demand for point-of-care cardiac testing kits are the key factors propelling the North America cardiac marker market growth.

Ongoing Research in Use of Exosomes as CVD Biomarkers

Hypoxia significantly affects exosome cargo and produces various proteins and miRNAs that indicate angiogenesis, growth, and progression for CVD through different signaling pathways. Exosomes has gathered the attention of researchers because they are relevant to intercellular communication under both physiological and pathological conditions. The upregulated exosome miRNAs miR-133a, miR-208a, miR-1, miR-499-5p, and miR-30a have been designated for the timely diagnosis of acute myocardial infarction (AMI). Further, derived exosomes namely, miR-192, miR-146a, miR-194, and miR-92b-5p are considered as potential biomarkers for HF.

Table 1. Exosomes as CVD Biomarkers

Biomarker Disease Function

miRNA-126, miRNA-223, and miRNA-320b Acute myocardial infarction Platelet activation and thrombus formation, endothelial damage, myocardial apoptosis, and fibroblast proliferation

miRNA-1, miRNA-21a/b, and miRNA-29b Acute myocardial infraction Myocardial apoptosis, fibroblast proliferation, and cardiac hypertrophy

miRNA-208a Acute myocardial infarction Cardiac hypertrophy and electrical conduction

miRNA-499 Acute myocardial infarction Myocardial apoptosis

miRNA-486 Acute myocardial infarction Myocardial apoptosis (protective)

miRNA-223-5p Acute myocardial infarction, atherosclerosis, and heart failure Cell proliferation, migration, apoptosis, and polarization; cardiomyocyte hypertrophy; and electrical conduction

miRNA-941 Acute coronary syndrome Cell proliferation and inflammation

miRNA-216a and miRNA-451 Coronary artery disease Endothelial damage and monocyte recruitment

miRNA-223-3p, miRNA-122-5p, and miRNA-93-5p Coronary artery disease Inflammation, migration and apoptosis, cardiomyocyte hypertrophy, electrical conduction, and cardiomyocyte apoptosis

miRNA-142-3p, miRNA-17-5p, and miRNA-126 Acute myocardial infarction and coronary artery disease Inflammation; cardiomyocyte hypertrophy; and cell proliferation, migration, and apoptosis

miRNA-133a Coronary artery disease Cell proliferation and differentiation, cardiac hypertrophy, and electrical conduction (arrhythmia)

Serpin G1, Serpin F2, and Cystatin C CD14 Heart failure and acute coronary syndrome Inflammation, decrease in kidney function, decrease in fibrinolysis, and thrombotic process

Source: Allen Press

In coronary artery disease (CAD) patients, upregulated exosome proteins—including fibrinogen beta/gamma chain, alpha-1-antichymotrypsin, and inter-alpha-trypsin inhibitor heavy chain—were evaluated as putative protein biomarkers. The function of exosomes in CVD pathogenesis through diverse intercellular communication mechanisms is gaining significant recognition. Several studies conducted in recent years have generated evidence supporting the association of exosomes with normal physiology (cardiac development, reticulocyte maturation, and myocardial angiogenesis) and pathophysiological processes, including ischemia/reperfusion (IR) injury, atherosclerosis, and cardiac remodeling. Stressful conditions such as hypoxia and inflammation can modulate biological exosome content and target cells, thereby contributing to improving or impairing cardiac function. The integration of exosome-based miRNAs and proteins in body fluids enables a comprehensive analysis of the potential biomarker role of these components in cardiovascular diseases. Therefore, the use of exosome biomarkers is emerging as a new approach for the diagnosis of CVDs.

Factor Hampering North American Cardiac Marker Market

Companies can submit an application for regulatory qualification for a cardiac marker to the FDA Biomarker Qualification Program for a specific application. Only the qualified marker can be used in multiple drug development programs without the need for the Center for Drug Evaluation and Research (CDER) approval to reconfirm the suitability of the markers.

Cardiac markers are widely used in epidemiological studies for completing the investigation of numerous stages of CVD. The process requires more careful handling and storage of valuable biological samples to obtain detailed information. Precise quality control measures are required to ensure that these samples are handled in appropriate storage conditions to avoid data loss. Cardiac marker studies depend on the integrity of samples and the manner of collection, processing, and storage, as archived samples are used in these studies. Handling, labeling, processing, aliquoting, storage, and transportation may affect study results. The sample must be placed on dry ice and shipped the same day. If the process is not carried out properly, it can impact the quality of the sample, subsequently hampering the outcomes. Therefore, strict validation protocols established by the US FDA and technical issues associated with sample collection and storage hamper the growth of the North America cardiac markers market.

• Based on disease, the North America cardiac marker market is divided into HIV testing, influenza testing, sexually transmitted diseases testing, hepatitis C virus testing, tropical diseases testing, respiratory infection testing, hospital-acquired infections, strep, and others. The market is further divided on the basis of molecular diagnostics into polymerase chain reactions (PCR), isothermal nucleic acid amplification technology (INAAT), and others. The respiratory infection testing segment held the largest market share in 2023.

• Based on product type, the North America cardiac markers market is segmented into reagents and kits, and analyzers. The analyzers segment held a larger share in 2023. The reagents and kits segment is expected to register a higher CAGR during 2023–2031.

• Based on biomarker type, the North America cardiac markers market is divided into troponin, creatine kinase-MB, myoglobin, B-type natriuretic peptide, and others. The troponin segment held the largest market share in 2023 and is estimated to register the highest CAGR in the market during 2023–2031.

• By indication, the market is segmented into congestive heart failure, myocardial infraction, acute coronary syndrome, and others. The congestive heart failure segment held the largest share of the market in 2023. The acute coronary syndrome segment is estimated to register the highest CAGR during 2023–2031.

• In terms of end user, the North America cardiac markers market is divided into hospitals, diagnostic laboratories, point-of-care testing facilities, and others. The hospitals segment held the largest market share in 2023. The diagnostic laboratories segment is estimated to register the highest CAGR in the market during 2023–2031.

North America Point-Of-Care Molecular Testing for Infectious Diseases Market: Regional Overview

The the developed healthcare system and the high acceptance of cardiac markers for diagnosing and predicting diseases. The growing geriatric population needs biomarker testing for detecting conditions such as acute myocardial infarction, thereby driving demand for testing products. The existence of key players such as Quidel Corporation and Danaher Corporation in the region is another factor contributing to the growth of this market. According to the World Health Organization (WHO), ~77 million adults over the age of 18 have type 2 diabetes, including 25 million prediabetes, which increases the possibility of cardiovascular diseases (CVDs) and puts additional pressure on the healthcare system. Furthermore, increasing strategies adopted by market players in this region to develop innovative cardiac biomarker tests are expected to contribute to the market growth in this region.

A few of the major primary and secondary sources referred to while preparing the report on the North America cardiac marker market are the World Bank Data, National Health Service (NHS), US Department of Health and Human Services (HHS), and WHO (World Health Organization).

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

Year of Publication:

Troponin Segment to Hold North America Cardiac Marker Market Share During 2023–2031

According to our new research study on ” North America Cardiac Marker Market Size and Forecast (2021–2031), Regional Share, Trend, and Growth Opportunity Analysis,” the market value is projected to grow from US$ 1.17 billion in 2023 to US$ 2.87 billion by 2031. The North America cardiac marker market is further anticipated to record a CAGR of 11.8% from 2023 to 2031. The rising prevalence of cardiovascular diseases and a surge in the demand for point-of-care cardiac testing kits are the key driving factors behind the market development.

North America cardiac marker market is segmented into the US, Canada, and Mexico. The US is expected to be among the largest contributors to the cardiac marker market in North America. The US holds the largest share of the cardiac marker market in North America, owing to increasing product development and growing government support for enhancing heart treatment. In addition, the growing prevalence of heart diseases and the risk involved have led to the market growth. According to the Centers for Disease Control and Prevention, heart disease is one of the leading causes of death in the US. As per the same source, one person dies every 36 seconds because of CVD, i.e., approximately 655,000 Americans die from heart diseases each year.

In 2021, about 695,000 people died of heart disease in the US. One in five myocardial infarctions (MI) are asymptomatic, resulting in nearly 200,000 silent myocardial infarctions each year in the US. Therefore, developing new technologies that enable early noninvasive detection of myocardial damage is crucial. Companies are currently focusing on identifying cardiac biomarkers as these lead to a better understanding of the pathophysiology of CVDs. The timing of troponin test results is critical in helping physicians quickly diagnose and effectively treat patients. For instance, Elecsys Troponin T-Gen 5 STAT, a cardiac biomarker from Roche Diagnostics, provides results in 9 minutes and helps in rapid decision-making.

In March 2024, the US Food and Drug Administration (FDA) gave 510(k) clearance to a new high-sensitivity troponin assay developed for Polymedco’s PATHFAST biomarker analyzer. With this approval, the test can be used in the US on Polymedco’s PATHFAST analyzer with patients’ whole blood and plasma samples. PATHFAST High Sensitivity Troponin-I results can also be used with other diagnostic information such as electrocardiogram, clinical findings, and patient symptoms to aid in diagnosing myocardial infarction.

Furthermore, the country has several hospitals and super specialty hospitals that offer diagnostic and treatment services for CVDs. The healthcare centers in the country offer facilities that are incorporated with artificial intelligence and other hi-tech technologies. Therefore, the aforementioned initiatives are anticipated to propel the growth of the market in the US during the forecast period.

Based on product type, the North America cardiac marker market is segmented into reagents and kits, and analyzers. The analyzers segment held the largest market share in 2023.

By biomarker type, the market is segmented into troponin, creatine kinase-MB, myoglobin, B-type natriuretic peptide, and others. The troponin segment held the largest share of the market in 2023.

In terms of indication, the market is segmented into congestive heart failure, myocardial infraction, acute coronary syndrome, and others. The blood sample segment held the largest market share in 2023.

In terms of end user, the market is segmented into hospitals, diagnostic laboratories, point-of-care testing facilities, and others. The hospitals segment held the largest market share in 2023.

Abbott Laboratories, F.Hoffmann-La Roche, Thermo Fischer Scientific Inc, Beckman Coulter Inc, Bio-Rad Laboratories Inc, Creative Diagnostics, Diazyme Laboratories Inc, Biomerieux SA, Hytest Ltd, and QuidelOrtho Corp are a few key companies profiled in the North America cardiac marker market report.

Companies operating in the North America cardiac marker market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the North America cardiac marker market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall North America cardiac marker market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below.

• In March 2024, Hytest Ltd expanded into North America with a subsidiary, Hytest North America. The company will launch local operations to better serve customers and meet growing demands. With a local team in the US, the company will strive to enhance accessibility to products and services, ensuring a smoother experience for valued customers in North America.

• In October 2023, Hytest Ltd launched latest troponin product, the recombinant chimeric human Cardiac Troponin binary Complex (Cat. # 8IFC20). This unique complex features the most stable part of cTnI (fragment 28-110) linked with TnC by a 20-aar flexible linker of the cTn I – C complex.

• In January 2023, HyTest offers 3 new clones for NT-proBNP epitopes 27-31 (MAb NT13) and 43-46 (MAbs NT45 and NT46). These new clones are working with a variety of our existing NT-proBNP antibodies in fluorescence, chemiluminescence, and lateral flow platforms. In addition, they have a very good correlation with existing commercially available proBNP assays.

o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the North America Cardiac Markers Market, thereby allowing players to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth the market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to products, segmentation, and industry verticals.

TABLE OF CONTENTS

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. North America Cardiac Marker Market Landscape
4.1 Overview
4.2 PEST Analysis
5. North America Cardiac Marker Market – Key Market Dynamics
5.1 North America Cardiac Marker Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Prevalence of Cardiovascular Diseases
5.2.2 Surge in Demand for Point-of-Care Cardiac Testing Kits
5.3 Market Restraints
5.3.1 Strict Validation and Technical Issues Related to Sample Collection and Storage
5.4 Market Opportunities
5.4.1 Investments in Cardiovascular Sector
5.5 Future Trends
5.5.1 Ongoing Research in Use of Exosomes as CVD Biomarkers
5.6 Impact analysis
6. North America Cardiac Marker Market Analysis
6.1 North America Cardiac Marker Market Revenue (US$ Million), 2021–2031
7. North America Cardiac Marker Market Analysis – by Product Type
7.1 Analyzers
7.1.1 Overview
7.1.2 Analyzers: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Reagents and Kits
7.2.1 Overview
7.2.2 Reagents and Kits: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
8. North America Cardiac Marker Market Analysis – by Biomarker Type
8.1 Troponin
8.1.1 Overview
8.1.2 Troponin: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Creatine Kinase-MB
8.2.1 Overview
8.2.2 Creatine Kinase-MB: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Myoglobin
8.3.1 Overview
8.3.2 Myoglobin: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
8.4 B-Type Natriuretic Peptide
8.4.1 Overview
8.4.2 B-Type Natriuretic Peptide: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
9. North America Cardiac Marker Market Analysis – by Indication
9.1 Congestive Heart Failure
9.1.1 Overview
9.1.2 Congestive Heart Failure: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Myocardial Infraction
9.2.1 Overview
9.2.2 Myocardial Infraction: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Acute Coronary Syndrome
9.3.1 Overview
9.3.2 Acute Coronary Syndrome: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
10. North America Cardiac Marker Market Analysis – by End User
10.1 Hospitals
10.1.1 Overview
10.1.2 Hospitals: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Diagnostic Laboratories
10.2.1 Overview
10.2.2 Diagnostic Laboratories: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
10.3 Point-of-Care Testing Facilities
10.3.1 Overview
10.3.2 Point-of-Care Testing Facilities: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
10.4 Others
10.4.1 Overview
10.4.2 Others: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
11. North America Cardiac Marker Market – Country Analysis
11.1 North America
11.1.1 North America Cardiac Marker Market Breakdown by Countries
11.1.2 North America Cardiac Marker Market Revenue and Forecast and Analysis – by Country
11.1.2.1 United States: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.1.1 United States: North America Cardiac Marker Market Breakdown by Product Type
11.1.2.1.2 United States: North America Cardiac Marker Market Breakdown by Biomarker Type
11.1.2.1.3 United States: North America Cardiac Marker Market Breakdown by Indication
11.1.2.1.4 United States: North America Cardiac Marker Market Breakdown by End User
11.1.2.2 Canada: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.2.1 Canada: North America Cardiac Marker Market Breakdown by Product Type
11.1.2.2.2 Canada: North America Cardiac Marker Market Breakdown by Biomarker Type
11.1.2.2.3 Canada: North America Cardiac Marker Market Breakdown by Indication
11.1.2.2.4 Canada: North America Cardiac Marker Market Breakdown by End User
11.1.2.3 Mexico: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.3.1 Mexico: North America Cardiac Marker Market Breakdown by Product Type
11.1.2.3.2 Mexico: North America Cardiac Marker Market Breakdown by Biomarker Type
11.1.2.3.3 Mexico: North America Cardiac Marker Market Breakdown by Indication
11.1.2.3.4 Mexico: North America Cardiac Marker Market Breakdown by End User
12. Industry Landscape
12.1 Overview
12.2 Recent Development Strategies
12.2.1 Overview
13. Cardiac Marker Market-Industry Landscape
13.1 Overview
13.2 Organic Growth Strategies
13.2.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Thermo Fisher Scientific Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Beckman Coulter Inc
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Bio-Rad Laboratories Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Creative Diagnostics
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Diazyme Laboratories, Inc.
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 bioMerieux SA
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 HyTest Ltd.
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 QuidelOrtho Corp
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About the Research Team
15.2 Glossary of Terms

LIST OF TABLES

Table 1. North America Cardiac Marker Market Segmentation
Table 2. Available POC Products in the US
Table 3. Exosomes as CVD Biomarkers
Table 4. United States: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million) – by Product Type
Table 5. United States: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million) – by Biomarker Type
Table 6. United States: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million) – by Indication
Table 7. United States: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 8. Canada: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million) – by Product Type
Table 9. Canada: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million) – by Biomarker Type
Table 10. Canada: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million) – by Indication
Table 11. Canada: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 12. Mexico: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million) – by Product Type
Table 13. Mexico: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million) – by Biomarker Type
Table 14. Mexico: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million) – by Indication
Table 15. Mexico: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 16. Recent Development Activities in the Cardiac Marker Market
Table 17. Recent Organic Growth Strategies in the Cardiac Marker Market
Table 18. Glossary of Terms, North America Cardiac Marker Market

LIST OF FIGURES

Figure 1. North America Cardiac Marker Market Segmentation, by Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Cardiac Marker Market Revenue (US$ Million), 2021–2031
Figure 5. North America Cardiac Marker Market Share (%) – by Product Type, 2023 and 2031
Figure 6. Analyzers: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 7. Reagents and Kits: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. North America Cardiac Marker Market Share (%) – by Biomarker Type, 2023 and 2031
Figure 9. Troponin: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Creatine Kinase-MB: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Myoglobin: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. B-Type Natriuretic Peptide: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Others: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. North America Cardiac Marker Market Share (%) – by Indication, 2023 and 2031
Figure 15. Congestive Heart Failure: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Myocardial Infraction: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 17. Acute Coronary Syndrome: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. Others: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. North America Cardiac Marker Market Share (%) – by End User, 2023 and 2031
Figure 20. Hospitals: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. Diagnostic Laboratories: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Point-of-Care Testing Facilities: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 24. North America Cardiac Marker Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 25. United States: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 26. Canada: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)
Figure 27. Mexico: North America Cardiac Marker Market – Revenue and Forecast to 2031 (US$ Million)

The List of Companies – North America Cardiac Markers Market
o Abbott Laboratories
o Beckman Coulter Inc
o Creative Diagnostics
o Bio-Rad Laboratories Inc
o Diazyme Laboratories Inc
o bioMerieux SA
o HyTest Ltd
o QuidelOrtho Corp
o Thermo Fisher Scientific Inc
o F. Hoffmann-La Roche Ltd

Reviews

There are no reviews yet.

Be the first to review “North America Cardiac Markers Market Size and Forecast (2021-2031)”